Lupin's share price gains over 3% as Citi is bullish on the stock; check details

Shares of Lupin rose over 3% intraday on Wednesday, March 3, as the pharma major received a bullish outlook from the global broking firm Citi. The upgrade was done on expectations of sustained margin strength and new launches for the US market.

During the intraday period, shares of Lupin was trading at 3.01% higher on the National Stock Exchange (NSE). The company settled at ₹2,009 apiece, jumping 2.86% on the 50-share index.

The broking expects the baseline EBITDA margins to improve, broadly based on two factors — loss reduction in adjacencies and complex generic launches.

According to Citi, although tariffs are unlikely, an imposition of 10% tariffs may hit Lupin’s US business EBITDA by around 500 basis points, the news report stated.

The company’s market capitalisation stood at ₹91,816.59 crore.

Lupin had touched its 52-week high of ₹2,402.90 on January 2, 2025. However, it had its one-year low of ₹1,493.30 on June 4, 2024.

Lupin had reported a 38.8% rise in its consolidated net profit or profit after tax (PAT) at ₹858.9 crore for the December quarter (Q3 FY25) against ₹618.7 crore logged in the corresponding quarter of the previous fiscal.

EBITDA, or earnings before interest, taxes, depreciation, and amortisation, jumped 32.1% to ₹1,409.6 crore. It was ₹1,067.3 crore in the corresponding quarter of the previous fiscal year.

EBITDA margin zoomed 408 basis points (bps) to 25.1% from 21%.

Lupin is a multinational pharmaceutical company that develops and sells generic and branded drugs, biotechnology products, and APIs. The company is headquartered in Mumbai, India. Lupin's focus areas are anti-infectives, diabetology, asthma, anti-tuberculosis, and paediatrics.